Annual Securities Report — FY2025
What 3-D Matrix,Ltd. reported for the period from 2025-05-01 to 2026-04-30.
Filed 2026-07-22View the original on EDINET
How much it says
52Typical
What moved here
20named for the first time
Its own wording
48terms
Which filing this is
35/ 35newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the consolidated fiscal year, the Company’s business revenue increased year on year, led by its hemostatic agent business, and it reported operating profit and profit attributable to owners of the parent. Research and development expenses increased, while cash and cash equivalents also rose.
Komori's summary of this document, not the document's own words.52Typical
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 35 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
76
Very detailed
88
Very detailed
33
Thin
38
Thin
0
Almost nothing
50
Typical
68
Detailed
27
Almost nothing
53
Typical
65
Detailed
50
Typical
R&D spend6億円Money spent making new things.
Cash left over4億円Cash from the business, less what went into equipment.
Spent on equipment29百万円Plants, machines — things meant to last.
Employees129Headcount at the end of this period.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.